Helix BioPharma Corp. Completes Fourth Dosing Cohort and Initiates Enrollment of the Next Cohort in U.S. Combination Treatment Study of Its Lung Cancer Drug Candidate L-DOS47

RICHMOND HILL, ONTARIO- Helix BioPharma Corp. (TSX, FSE: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that the Safety Review Committee (“SRC”) reviewed safety data from the fourth dosing cohort of the Company’s LDOS001 study and recommended that Helix begin enrollment of patients into the fifth dosing cohort. LDOS001 is a dose escalation study of L-DOS47 with pemetrexed and carboplatin in recurrent or metastatic non-squamous non-small cell lung cancer. Patients enrolled in the fifth dosing cohort will receive the next L-DOS47 dose level which is 6.0 micrograms of L-DOS47 per kilogram of patient body weight.